此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

药物相关急性肾损伤的多医院电子决策支持 (MEnD-AKI)

2026年10月16日 更新者:Sandra Kane-Gill, PharmD, MSc, FCCP, FCCM、University of Pittsburgh

药物相关急性肾损伤多医院电子决策支持 (MEnD-AKI)

This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.

研究概览

地位

完全的

条件

干预/治疗

详细说明

Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with D-AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with D-AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with D-AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. Additionally, the investigators will assess cost-effectiveness and physicians' perception of the pharmacist-led service.

The primary outcome is Major Adverse Kidney Events within 30 days of randomization (MAKE30), defined as defined as a composite of death, new kidney replacement therapy, or final serum creatinine ≥150% of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Key secondary outcomes include: progression of AKI from time of Level B intervention (first alert generated) to hospital discharge, AKI intensity (duration of AKI by all stages, duration of AKI stage 2, and duration of AKI stage 3), and nephrotoxic burden.

研究类型

介入性

注册 (实际的)

698

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Altoona、Pennsylvania、美国、16601
        • UPMC Altoona
      • Farrell、Pennsylvania、美国、16121
        • UPMC Horizon
      • McKeesport、Pennsylvania、美国、15132
        • UPMC McKeesport
      • New Castle、Pennsylvania、美国、16105
        • UPMC Jameson
      • Pittsburgh、Pennsylvania、美国、15232
        • UPMC Shadyside
      • Pittsburgh、Pennsylvania、美国、15213
        • UPMC Magee
      • Pittsburgh、Pennsylvania、美国、15213
        • UPMC Presbyterian/Montefiore
      • Williamsport、Pennsylvania、美国、17701
        • UPMC Williamsport

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Physician-subject Inclusion

  • Physicians employed at UPMC hospital systems
  • Attending physicians of record who care for patients across multiple units outside ICU/ED
  • Physician cares for 1 or more patient receiving a system alert identifying high-risk for AKI

Physician-subject Exclusion

  • Physicians of record who only care for ICU or ED patients
  • Physicians who primarily provide care for transplant (heart, kidney, liver, etc.) patients
  • Physicians who primarily provide consult services only (dermatology, rehabilitation, etc.)

Patient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.

Patient-subject Inclusion

  • System alert identifying risk for AKI
  • Patient has attending physician who is participating in the randomized clusters
  • After initial patient inclusion, an individual patient will not be eligible for re-inclusion until after 90 days. Re-inclusion will only be allowed if a separate hospital admission/encounter occurs and only starting on day 91

Patient-subject Exclusion

• Patients with end stage renal disease on admission, baseline eGFR <15, comfort measures only, or died before the intervention could be delivered

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Protocolized stage-based intervention

The intervention uses an automated alerting system to identify patients of enrolled physicians: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval.

Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.

The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.

有源比较器:Usual Care

A Cerner EMR-based AKI passive alert which is standard of care at UPMC.

Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians
大体时间:up to 30 days

Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so ~ 3000 patients were included for the per protocol analysis to be impactful.

up to 30 days

次要结果测量

结果测量
措施说明
大体时间
Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge
大体时间:up to 30 days

Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first.

Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first.

Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first.

The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert.

up to 30 days
AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3
大体时间:up to 30 days

AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians.

up to 30 days
Nephrotoxic Burden
大体时间:up to 30 days

Drug.days* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients.

*Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day.

up to 30 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 首席研究员:Azra Bihorac, MD, MS、University of Florida
  • 首席研究员:Sandra L Kane-Gill, PharmD, MS、University of Pittsburgh

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年2月15日

初级完成 (实际的)

2025年7月15日

研究完成 (实际的)

2025年7月15日

研究注册日期

首次提交

2024年2月8日

首先提交符合 QC 标准的

2024年2月15日

首次发布 (实际的)

2024年2月20日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年10月16日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • STUDY20120008
  • R01DK121730 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.